Skip to main content

Table 1 Relationship between NDRG2 promoter methylation, patient clinical characteristics, PA invasiveness and NDRG2 mRNA expression

From: N-myc downstream-regulated gene 2 (NDRG2) promoter methylation and expression in pituitary adenoma

  NDRG2 gene methylation
  Number of patients M (%) U (%) p-value
Cases 119 27 (22.69) 92 (77.31)  
Age (years)
 ≤60 48 13 (27.08) 35 (72.92) 0.368
 >60 70 14 (20.00) 56 (80.00)
Gender
 Female 68 15 (22.06) 53 (77.94) 0.850
 Male 51 12 (23.53) 39 (76.47)
PA function
 Secreting 61 15 (24.59) 46 (75.41) 0.612
 Non-secreting 58 12 (20.69) 46 (79.31)
Relapse
 Appear 10 2 (20.00) 8 (80.00) 0.832
 None 109 25 (22.94) 84 (77.06)
Prolactinoma
 Appear 37 9 (24.32) 28 (75.68) 0.952
 None 24 6 (25.00) 18 (75.00)
Acromegaly
 Appear 12 4 (33.33) 8 (66.67) 0.433
 None 49 11 (22.45) 38 (77.55)
Cushing syndrome
 Appear 1 0 (0.00) 1 (100.00) 0.565
 None 60 15 (25.00) 45 (75.00)
Hormones
 PRL 37 9 (24.32) 28 (75.68) 0.801
 IGF-1 2 0 (0.00) 2 (100.00) 0.401
 GH 6 2 (33.33) 4 (66.67) 0.639
 ACTH 1 0 (0.00) 1 (100.00) 0.556
 Multiple 13 4 (30.77) 9 (69.23) 0.616
Invasiveness
 Invasive 41 10 (24.39) 31 (75.61) 0.452
 Non-invasive 19 3 (15.79) 16 (84.21)
NDRG2 mRNA expression
 Low 22 3 (13.64) 19 (86.36)  
 Medium 50 13 (26.00) 37 (74.00) 0.458
 High 37 7 (18.92) 30 (81.08)
  1. M methylated, U unmethylated, PRL prolactin, IGF-1 insulin-like grow factor 1, GH growth hormone, ACTH adrenocorticotropic hormone, multiple PAs secreting more than one hormone